Magenta Therapeutics Inc (DNTH)

$28.43

-0.62

(-2.13%)▲

Live

Performance

  • $28.30
    $29.26
    $28.43
    downward going graph

    0.46%

    Downside

    Day's Volatility :3.28%

    Upside

    2.84%

    downward going graph
  • $6.58
    $33.77
    $28.43
    downward going graph

    76.86%

    Downside

    52 Weeks Volatility :80.52%

    Upside

    15.81%

    downward going graph

Returns

PeriodMagenta Therapeutics IncIndex (Russel 2000)
3 Months
3.9%
0.0%
6 Months
25.0%
0.0%
1 Year
139.49%
0.0%
3 Years
351.09%
-23.0%

Highlights

Market Capitalization
823.1M
Book Value
$12.20
Earnings Per Share (EPS)
-1.93
Wall Street Target Price
50.1
Profit Margin
0.0%
Operating Margin TTM
-1191.84%
Return On Assets TTM
-19.84%
Return On Equity TTM
-27.33%
Revenue TTM
4.1M
Revenue Per Share TTM
0.2
Quarterly Revenue Growth YOY
92.30000000000001%
Gross Profit TTM
6.4M
EBITDA
-68.7M
Diluted Eps TTM
-1.93
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.21
EPS Estimate Next Year
-2.76
EPS Estimate Current Quarter
-0.55
EPS Estimate Next Quarter
-0.6

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Magenta Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 76.22%

Current $28.43
Target $50.10

Company Financials

FY21Y/Y Change
Revenue
1.5M
-
Net Income
-13.1M
↓ 82.51%
Net Profit Margin
-888.14%
-
FY22Y/Y Change
Revenue
6.4M
↑ 334.76%
Net Income
-28.5M
↑ 117.22%
Net Profit Margin
-443.76%
↑ 444.38%
FY23Y/Y Change
Revenue
2.8M
↓ 55.96%
Net Income
-43.6M
↑ 52.95%
Net Profit Margin
-1.5K%
↓ 1097.46%
Q1 FY23Q/Q Change
Revenue
476.0K
↓ 59.49%
Net Income
-29.2M
↑ 188.36%
Net Profit Margin
-6.1K%
↓ 5267.21%
Q2 FY23Q/Q Change
Revenue
969.0K
↑ 103.57%
Net Income
-3.3M
↓ 88.74%
Net Profit Margin
-338.91%
↑ 5789.24%
Q3 FY23Q/Q Change
Revenue
924.0K
↓ 4.64%
Net Income
-14.8M
↑ 349.54%
Net Profit Margin
-1.6K%
↓ 1258.82%
Q4 FY23Q/Q Change
Revenue
457.0K
↓ 50.54%
Net Income
-10.6M
↓ 28.45%
Net Profit Margin
-2.3K%
↓ 713.65%
Q1 FY24Q/Q Change
Revenue
874.0K
↑ 91.25%
Net Income
-13.7M
↑ 30.15%
Net Profit Margin
-1.6K%
↑ 738.38%
Q2 FY24Q/Q Change
Revenue
1.9M
↑ 113.16%
Net Income
-17.6M
↑ 28.07%
Net Profit Margin
-945.09%
↑ 627.91%
FY18Y/Y Change
Total Assets
157.3M
↑ 188.84%
Total Liabilities
11.7M
↑ 181.63%
FY19Y/Y Change
Total Assets
161.5M
↑ 2.67%
Total Liabilities
20.3M
↑ 74.2%
FY20Y/Y Change
Total Assets
161.6M
↑ 0.07%
Total Liabilities
17.7M
↓ 12.83%
FY21Y/Y Change
Total Assets
9.5M
↓ 94.15%
Total Liabilities
26.7M
↑ 50.74%
FY22Y/Y Change
Total Assets
83.1M
↑ 779.38%
Total Liabilities
127.5M
↑ 377.45%
FY23Y/Y Change
Total Assets
179.4M
↑ 115.86%
Total Liabilities
10.5M
↓ 91.74%
Q1 FY23Q/Q Change
Total Assets
83.4M
↑ 0.4%
Total Liabilities
6.0M
↓ 95.31%
Q2 FY23Q/Q Change
Total Assets
78.6M
↓ 5.76%
Total Liabilities
4.0M
↓ 32.56%
Q3 FY23Q/Q Change
Total Assets
192.5M
↑ 144.74%
Total Liabilities
14.1M
↑ 249.06%
Q4 FY23Q/Q Change
Total Assets
179.4M
↓ 6.78%
Total Liabilities
10.5M
↓ 25.18%
Q1 FY24Q/Q Change
Total Assets
382.5M
↑ 113.18%
Total Liabilities
9.8M
↓ 7.21%
Q2 FY24Q/Q Change
Total Assets
369.0M
↓ 3.53%
Total Liabilities
10.7M
↑ 9.88%
FY21Y/Y Change
Operating Cash Flow
-9.9M
↓ 84.53%
Investing Cash Flow
-33.0K
-
Financing Cash Flow
14.9M
↓ 77.99%
FY22Y/Y Change
Operating Cash Flow
-29.1M
↑ 193.52%
Investing Cash Flow
-59.8M
↑ 181169.7%
Financing Cash Flow
96.7M
↑ 548.31%
Q1 FY23Q/Q Change
Operating Cash Flow
-20.0M
↑ 125.51%
Investing Cash Flow
18.1M
-
Financing Cash Flow
-15.6M
↓ 13699.13%
Q2 FY23Q/Q Change
Operating Cash Flow
-6.5M
↓ 67.21%
Investing Cash Flow
21.9M
↑ 20.59%
Financing Cash Flow
0.0
↓ 100.0%

Technicals Summary

Sell

Neutral

Buy

Magenta Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Magenta Therapeutics Inc
Magenta Therapeutics Inc
11.0%
25.0%
139.49%
351.09%
185.08%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Magenta Therapeutics Inc
Magenta Therapeutics Inc
NA
NA
NA
-2.21
-0.27
-0.2
NA
12.2
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Magenta Therapeutics Inc
Magenta Therapeutics Inc
Buy
$823.1M
185.08%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Magenta Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 457.0K → 1.86M (in $), with an average increase of 50.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -10.56M → -17.60M (in $), with an average decrease of 29.1% per quarter

Company Information

magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.

Organization
Magenta Therapeutics Inc
Employees
53
CEO
Mr. Marino Garcia M.B.A.
Industry
Miscellaneous

Discover More

FAQs